Benefit of adding Cureety Techcare telemonitoring to usual care during injectable anticancer treatment: the OPTIMACURE multicentric French prospective randomized study
Study description
A French prospective, randomized, open-label, multicentric study to evaluate the effectiveness of standard of care with Cureety (RPM), compared to standard of care alone OPTIMA program, to reduce the number of outgoing telephone calls during the first 8 weeks of intravenous treatment.
Key results
- 127 patients in RPM group, 65 in control group (OPTIMA)
- Reduction of the total number of calls in RPM group (mean diff=-1.25, p<0.001), and specifically the number of call for visit preparation (mean diff=-2.7, p<0.001)
- Increase number of calls for inter-cycles toxicities (mean diff=+1.48, p<0.001)
→ Optimized patient management
Publication
Protocol part only: Faveyrial et al., 2025, BMC | https://link.springer.com/article/10.1186/s12913-025-13661-1
